Top 10 Reasons Biological Product Approvals Get Delayed in India — And How to Avoid Them

Time Is Money — And Preventable Delays Are Common

India’s Biological product approval timelines are frequently longer than companies anticipate. While CDSCO has made significant progress in recent years — introducing electronic submissions, faster SEC meeting schedules, and more transparent communication — delays remain prevalent, and most of them are preventable.

Based on CliniExperts’ experience managing Biological product registrations across Biosimilars, monoclonal antibodies, vaccines, and advanced therapies, we have identified the ten most common causes of approval delays. Understanding these failure modes is the first step to avoiding them.

Reason 1: Dossier Deficiencies in the Quality Module

The most common cause of regulatory delays is a deficient quality (Module 3 CTD) submission. Biological products have significantly higher analytical data requirements than small molecules, and Indian submissions often underestimate the depth expected by CDSCO reviewers.

The most frequent quality-related deficiencies include incomplete process characterisation and validation data, insufficient stability data under ICH and India-specific climatic conditions (Zone IVB), inadequate control of biological activity assays, and missing or poorly justified specifications for critical quality attributes (CQAs). Companies should conduct a pre-submission quality dossier gap analysis against CDSCO’s published expectations and recent deficiency letter patterns before filing.

Reason 2: Product Classification Errors

India’s biological product classification system has nuances that are not always obvious to companies entering from other regulatory environments. A product classified as a Drug in the EU may need to be evaluated as a Medical Device, a combination product, or a different Drug schedule in India.

Errors in classification at the time of application can result in the application being returned or redirected, losing months of review time. CAR-T therapies, gene therapy products, stem cell preparations, and combination Drug-Device Biological products are particularly prone to classification uncertainty. Seeking a pre-submission classification opinion from CDSCO — or consulting experienced Regulatory professionals — before filing eliminates this risk.

Reason 3: Poor Localisation Strategy

Applying a global dossier to India without meaningful localisation is one of the most common strategic errors. Indian patients differ from Western populations in ways that CDSCO reviewers are trained to evaluate — body weight distributions affecting dosing, genetic polymorphisms affecting pharmacokinetics, and disease pathologies that may differ in severity or progression.

A dossier that lacks ethnic sensitivity data, Indian patient subgroup analyses, or a justified rationale for why foreign data is representative of the Indian population will routinely attract deficiency letters. The investment in India-specific data generation or at minimum a well-argued ethnic bridging strategy delivers significant regulatory returns.

Reason 4: GMP Readiness Gaps

CDSCO requires that manufacturing facilities for biological products — whether Indian or foreign — meet the GMP standards prescribed under Schedule M of the Drugs and Cosmetics Act. For foreign manufacturers, this means the facility must either hold a valid WHO-GMP certificate, have been inspected by a recognised SRA, or be prepared to receive a CDSCO inspection.

GMP-related delays arise when facilities have outstanding observations from prior inspections, when the CDSCO inspection report identifies deficiencies that must be addressed before approval, or when companies fail to notify CDSCO of manufacturing site changes after initial approval. Proactive GMP readiness assessment, including a pre-inspection audit against CDSCO’s inspection expectations, is essential.

Reason 5: Weak Scientific Justifications

CDSCO’s Scientific Expert Committee is staffed by highly qualified academic, Clinical, and regulatory scientists. Presentations and dossiers that contain unsupported assertions, circular arguments, or conclusions that exceed what the data actually demonstrates will be challenged at the SEC meeting.

Common examples of weak scientific justifications include extrapolation of indications without adequate mechanistic rationale, immunogenicity risk assessments that understate the potential for antibody formation, and clinical bridging arguments that do not adequately address ethnic differences. Every scientific justification in the dossier should be capable of withstanding expert scrutiny.

Reason 6: Multi-Authority Coordination Failures

As described in Article 3 of this series, India’s Biological Regulatory system involves multiple authorities. Delays frequently occur because companies pursue CDSCO approval without simultaneously progressing RCGM, IBSC, or NIB interactions that are also required.

The most damaging scenario is receiving CDSCO marketing authorisation only to discover that RCGM approval for the manufacturing process, or NIB lot release certification, will add another 12 to 18 months before commercial launch. Integrated project plans that map all parallel regulatory workstreams from Day 1 are essential.

Reason 7: Inadequate Pharmacovigilance Infrastructure

CDSCO’s requirements for Biological product Pharmacovigilance have been progressively strengthened, and the Pharmacovigilance Programme of India (PvPI) now expects companies to have India-specific Pharmacovigilance systems — not simply a reference to their global PSUR submission process.

Deficiencies in the Risk Management Plan (RMP), absence of a designated Indian Pharmacovigilance contact, and failure to define India-specific signal detection processes are increasingly common causes of pre-approval queries and post-approval compliance actions.

Reason 8: Insufficient Clinical Data in Indian Populations

India’s New Drugs and Clinical Trials Rules, 2019 strongly preference data from Indian patients. For Biological products categorised as New Drugs — which includes most biosimilars seeking first approval in India and all advanced therapies — the absence of Indian Clinical Data creates a significant evidentiary gap.

Companies seeking waivers of Indian Clinical Data requirements must provide robust scientific justification, and CDSCO has become increasingly conservative in granting such waivers, particularly in therapeutic areas where ethnic differences in response or safety profile are plausible. Early engagement with CDSCO on the Clinical Data strategy — including a pre-IND meeting where possible — is strongly recommended.

Reason 9: Labelling and Packaging Non-Compliance

India has detailed labelling requirements for Biological products that differ from requirements in other major markets. Common labelling-related deficiencies include missing mandatory statements in Hindi and the local language of the primary market, incorrect or absent storage condition statements, non-compliant batch number formats, and absence of required barcode and QR code elements being phased in under CDSCO’s track-and-trace initiatives.

Labelling deficiencies typically arise late in the review process, when applicants submit draft artwork for CDSCO approval, and can add two to four months to the approval timeline. Investing in a labelling compliance review against Indian requirements — conducted in parallel with the main dossier review — avoids this avoidable delay.

Reason 10: Reactive Rather Than Proactive Regulatory Management

The final — and perhaps most systemic — cause of delays is a reactive Regulatory management approach. Companies that submit their dossier and wait passively for CDSCO’s response, without proactive follow-up, pre-submission meetings, and ongoing regulatory intelligence monitoring, consistently experience longer timelines than companies that maintain active engagement with the regulatory process.

Proactive regulatory management in India includes:

1. Conducting pre-submission meetings with CDSCO to align on data requirements before investing in full dossier preparation
2. Monitoring CDSCO’s published agendas and SEC meeting schedules to anticipate when an application will be reviewed
3. Maintaining relationships with regulatory affairs professionals who have established channels of communication with CDSCO staff
4. Monitoring the Regulatory intelligence landscape for new guidance, draft guidelines, and policy circulars that affect the submission

Conclusion: Prevention Is the Best Regulatory Strategy

The good news is that most Biological product approval delays in India are preventable. They stem not from the inherent complexity of CDSCO’s requirements — which are science-driven and generally well-documented — but from inadequate preparation, insufficient localisation, and fragmented regulatory project management.

Companies that invest in rigorous pre-submission planning, multi-authority coordination, India-specific data strategies, and active Regulatory management will consistently achieve faster approvals with fewer deficiency letters. In a therapeutic landscape where timing to market has direct patient and commercial consequences, that investment pays itself many times over.

Ready to navigate India’s biologicals regulatory landscape? CliniExperts Services brings deep expertise across CDSCO, RCGM, DBT, and NIB pathways. Contact us for a complimentary regulatory feasibility assessment.  contact@cliniexperts.com